Protein clues in kidney disease could predict anemia and heart risks
NCT ID NCT07676526
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study examines how the severity of chronic kidney disease (CKD) affects the breakdown of a protein called FGF23, which is linked to bone health, anemia, and heart problems. Researchers will measure different forms of FGF23 in blood samples from 80 men with CKD stages 3a to 5. The goal is to see if changes in FGF23 cleavage can serve as new biomarkers for complications like anemia and cardiovascular disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify new biomarkers to better predict anemia and heart problems in people with chronic kidney disease.
What could go wrong
This is a small, early-stage observational study, so findings may not lead to immediate clinical changes or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Saint-Etienne
Saint-Etienne, 42055, France
Contact Phone: •••-•••-•••• Email: •••••@•••••